Nandrolone Decanoate is unique in that 5a -reductase, the enzyme which converts testosterone to the more-potent DHT, actually converts nandrolone to a less-potent compound. Therefore this AAS is somewhat deactivated in the skin, scalp, and prostate, and these tissues experience an effectively-lower androgen level than the rest of the body. Therefore, for the same amount of activity as another drug at the androgen receptors (ARs) in muscle tissue, Deca gives less activity in the scalp, skin, and prostate. Thus, it is the best choice for those particularly concerned with these things.
Heavy consumption of the essential amino acid lysine (as indicated in the treatment of cold sores) has allegedly shown false positives in some and was cited by American shotputter C. J. Hunter as the reason for his positive test, though in 2004 he admitted to a federal grand jury that he had injected nandrolone.  A possible cause of incorrect urine test results is the presence of metabolites from other AAS, though modern urinalysis can usually determine the exact AAS used by analyzing the ratio of the two remaining nandrolone metabolites. As a result of the numerous overturned verdicts, the testing procedure was reviewed by UK Sport . On October 5, 2007, three-time Olympic gold medalist for track and field Marion Jones admitted to use of the drug, and was sentenced to six months in jail for lying to a federal grand jury in 2000. 
Insulin glargine is not appropriate for intravenous administration (IV); the prolonged activity of insulin glargine is dependent on injection into subcutaneous tissue. IV administration of the usual subcutaneous dosage could result in severely low blood glucose concentrations. Long-acting insulin preparations should not be used for diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), diabetic coma, or other emergencies requiring rapid onset of insulin action. Several types, routes, and frequencies of administration of insulin have been studied in patients with DKA and HHS; however, the American Diabetes Association recommends that regular insulin (versus the rapid-acting analogs) by continuous intravenous infusion be used to treat these conditions unless they are considered mild. Regular insulin is also preferred for those patients with poor tissue perfusion, shock, or cardiovascular collapse, or in patients requiring insulin for the treatment of hyperkalemia. Insulin glargine should not be used for continuous subcutaneous insulin infusion (CSII) administration; only quick-acting insulins (., regular insulin, insulin lispro, insulin glulisine, and insulin aspart) should be used by this route of administration.